Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma Interventions: Drug: Sintilimab, bevacizumab, gemcitabine; Radiation: IMRT Sponsors: Zhejiang Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Hospitals | Intensity-Modulated Radiation Therapy | Nasopharyngeal Cancer | Research